Difference between revisions of "Malignant solid neoplasm, EGFR-mutated"
Jump to navigation
Jump to search
m (Jwarner moved page Solid malignant neoplasm, EGFR-mutated to Malignant solid neoplasm, EGFR-mutated) |
m |
||
Line 37: | Line 37: | ||
===References=== | ===References=== | ||
# '''MyPathway:''' Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study. J Clin Oncol. 2018 Feb 20;36(6):536-542. Epub 2018 Jan 10. [https://doi.org/10.1200/JCO.2017.75.3780 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/29320312/ PubMed] [https://clinicaltrials.gov/study/NCT02091141 NCT02091141] | # '''MyPathway:''' Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study. J Clin Oncol. 2018 Feb 20;36(6):536-542. Epub 2018 Jan 10. [https://doi.org/10.1200/JCO.2017.75.3780 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/29320312/ PubMed] [https://clinicaltrials.gov/study/NCT02091141 NCT02091141] | ||
− | [[Category: | + | [[Category:Malignant solid neoplasm, EGFR-mutated regimens]] |
[[Category:Biomarker-specific pages]] | [[Category:Biomarker-specific pages]] | ||
[[Category:Malignant solid neoplasm]] | [[Category:Malignant solid neoplasm]] | ||
[[Category:Site-agnostic regimens]] | [[Category:Site-agnostic regimens]] |
Revision as of 16:28, 21 September 2023
1 regimens on this page
1 variants on this page
|
All lines of therapy
Erlotinib monotherapy
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Hainsworth et al. 2018 (MyPathway) | 2014-2016 | Phase 2a, fewer than 20 pts in this arm |
Biomarker eligibility criteria
References
- MyPathway: Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study. J Clin Oncol. 2018 Feb 20;36(6):536-542. Epub 2018 Jan 10. link to original article contains dosing details in manuscript PubMed NCT02091141